Anupam Rasayan India Ltd (ANURAS) Q1 FY27 Earnings Call: Order Book Crosses Rs. 18,000 Cr, Guides 20-25% Organic Revenue Growth

Anupam Rasayan India Ltd held its Q1 FY27 earnings call on August 14, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Broad-Based Revenue Growth With Stable Margins

• Consolidated total income of Rs.668 Cr in Q1 FY 2026-2027, up 36% YoY from Rs.491 Cr in Q1 FY 2025-2026; revenue from operations at Rs.655 Cr.
• EBITDA of Rs.175 Cr in Q1 FY 2026-2027, up 35% YoY, with EBITDA margin maintained at 26% — broadly stable despite an expanded depreciation base from J-Hawk.
• PAT of Rs.51 Cr in Q1 FY 2026-2027, up 6% YoY from Rs.49 Cr in Q1 FY 2025-2026; PAT margin ~8%.
• Cash profits of Rs.64 Cr in Q1 FY 2026-2027 vs. Rs.56 Cr in Q1 FY 2025-2026, reflecting improved cash generation from operations.
• Standalone gross margin of 58% in Q1 FY 2026-2027, up sharply YoY, driven by a favourable mix shift toward performance materials; management cited EBITDA as the more stable tracking metric.
• Depreciation expense rose in Q1 FY 2026-2027 due to an expanded asset base and higher depreciation at J-Hawk, constraining PAT growth relative to revenue.

Rs.18,000 Cr Backlog; LOIs Signed With BASF and Dhaval

• Cumulative signed LOIs and contracts of ~Rs.18,000 Cr in potential business over their respective tenures, per management disclosure on the Q1 FY 2026-2027 call.
• Signed LOI with BASF for potential long-term supply of a specialty chemical product, strengthening the partnership pipeline.
• Signed LOI with Dhaval for ~$300 Mn spread over 10 years, with commercialisation expected to begin in FY 2026-2027 — management described it as "a potential long-term opportunity of approximately $300 million spread over 10 years."
• Order book revenue contributed ~Rs.400 Cr in FY 2025-2026; management guided this to be "significantly higher" in FY 2026-2027 at ~25–30% of total revenue, eventually reaching ~30% as the base grows.
• New LOI product to be commercialised in H2 FY 2026-2027, with technology already developed and piloted; revenue expected to ramp meaningfully over the next two to three years (by ~FY 2028-2029).

J-Hawk Integration Underway; Bliss Merger Nearing Close

• J-Hawk Fine Chemical contributed ~Rs.145 Cr revenue in Q1 FY 2026-2027, with EBITDA margin of 19–20% and PAT of ~Rs.9–10 Cr; FY 2026-2027 is the first full year of consolidation and integration.
• Bliss GVS Pharma merger expected to be consummated by H1 Sep 2026 (within FY 2026-2027); Bliss brings 62 molecules in pipeline, including 48+ targeting regulated markets.
• Management targets improving Bliss utilisation from ~30% to 60–70% over the next 2–3 fiscal years (through FY 2028-2029); Q1 FY 2026-2027 growth was fully organic, with no client introductions from Anupam yet.
• Bliss acquisition funded with Rs.300 Cr of debt plus an equity-linked instrument; Anupam retains a right to buy out instrument holders at any time; Bliss holds over $20 Mn cash and is debt-free.
• Bain and Co engaged as global consulting firm to run the PMO and IMO for J-Hawk integration, assessing joint capabilities in semicon, defense, and performance materials.
• Management declined to provide API acquisition specifics; exploration remains at an early stage, with no confirmed target as of Q1 FY 2026-2027.

ETFA Flow Chemistry Milestone; Semicon Gaining Traction

• Commercialised ethyl trifluoroacetate (ETFA) using flow chemistry in Q1 FY 2026-2027, claiming to be the first company globally to achieve this; technology improves safety, product quality, and environmental footprint.
• ETFA total addressable market estimated at ~$500 Mn across pharma, agro, electronics, and semiconductors; management targets 5–10% share initially, scaling to 15–30% over time with an upward bias on margins vs. existing CDMO business.
• Commercialised 1 new pharma product and 2 new performance material products in Q1 FY 2026-2027, contributing to near-term revenue diversification.
• R&D pipeline of 65+ pharma and polymer molecules in pilot stage; more than 10 molecules commercialised in this segment over the last two fiscal years (FY 2024-2025 and FY 2025-2026).
• Semiconductor business described as "growing very fast" as of Q1 FY 2026-2027, with strong traction from existing and new customers; J-Hawk acquisition accelerating growth via a validated semicon product portfolio.
• Semicon commercial validation for Anupam's own products is still in process; management did not specify a timeline for completion.

Major Capex Cycle Complete; Working Capital Expected to Improve

• Major capex cycle completed for the existing Anupam platform; no significant future capex foreseen — management will be selective, evaluating new investments based on customer visibility and strategic returns.
• Standalone capex of Rs.70–80 Cr per annum guided for FY 2026-2027 and FY 2027-2028, limited to maintenance and repurposing.
• Interest cost run rate for FY 2026-2027 expected at Q1 FY 2026-2027 levels, described by management as a "fairly representative run rate."
• J-Hawk is well-capitalised and unlevered; no requirement for Anupam to fund J-Hawk's capex in FY 2026-2027 or FY 2027-2028.
• Working capital expected to improve further in FY 2026-2027, supported by an evolving business mix (increasing pharma and performance materials share) and tighter inventory and receivable management.
• Depreciation run rate may be subject to review due to J-Hawk's historical depreciation periods, but is not driven by new capital expenditure.

FY27 Organic Revenue Growth of 20–25% Plus J-Hawk Uplift

• Organic revenue growth of 20–25% guided for FY 2026-2027 from the three existing entities (Anupam, Tanfac, J-Hawk), with an additional 10–15% uplift from the full-year inclusion of J-Hawk.
• Q1 FY 2026-2027 organic growth (ex-J-Hawk) was single-digit, which management attributed to a seasonally tepid quarter; the guided trajectory is expected to materialise from the coming quarters.
• Order book contribution guided at ~25–30% of total revenue for FY 2026-2027, eventually reaching ~30% as the base grows.
• Agri business demand is robust and expected to deliver stable growth in FY 2026-2027, though its portfolio contribution will decline as performance materials and pharma outpace it.
• Management priorities for FY 2026-2027 and beyond: commercialise the R&D pipeline, increase contribution from performance materials and pharma, deepen customer relationships, and invest in advanced technologies.
• Bliss post-merger integration timelines remain uncertain; management will arrange investor outreach with Bliss management post-consummation, likely in Q2 or Q3 FY 2026-2027.